Conatus (CNAT) Stock Surges 44 percent

Conatus Pharmaceuticals Inc. (CNAT) stock is exploding higher by more than 44% Thursday, as the biotechnology firm today announced top-line results from NAFLD/NASH clinical trial of Emricasan, a first-in-class, orally active pan-caspase protease inhibitor. “With these results from the NAFLD/NASH trial, we have confirmed that the optimal dose of emricasan is consistent across different etiologies,” […] View the full post at: Conatus (CNAT) Stock Surges 44 percent Related posts: California’s 1st-Time Home Buyer Affordability Surges in QI Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock Congress To Hold Hearing on the Circumstances Behind Thursday’s Stock Market Plunge